Literature DB >> 33819954

Role of obesity-induced inflammation in the development of insulin resistance and type 2 diabetes: history of the research and remaining questions.

Jieun Kim1, Jongsoon Lee1.   

Abstract

The prevalence of obesity has increased alarmingly both worldwide and in Korea. This has also dramatically increased the prevalence of chronic obesity-associated diseases, including type 2 diabetes (T2D). Extensive studies on the molecular etiology of T2D have revealed several potential mechanisms by which obesity induces the development of insulin resistance and T2D. One of these is low-grade chronic inflammation. Studies hinting at the existence of this phenomenon were first published about 30 years ago. Ten years later, several seminal papers confirmed its existence, which then led to a rapid and massive escalation of research in this field. Today, the notion that obesity-induced inflammation mediates T2D is now well-accepted. This paper will review the key developments in this field, including the discovery that obesity-induced inflammation and insulin resistance is mainly regulated by adipose tissue-resident immune cells, particularly those in visceral adipose tissue. This review further details the research areas, including (1) the obesity-related factors that induce adipose tissue macrophage (ATM) inflammation, (2) the precise effector functions by which adipose tissue immune cells promote insulin resistance, (3) whether there are early immunological events that have an outsize effect on later events and could be targeted to arrest the development of insulin resistance, (4) the roles played by nonimmunological functions of ATMs and other immune cells, and (5) whether there are noncanonical immune responses to obesity (i.e., immune responses that are unique to obesity and cannot be detected by following the discoveries in the classical immunity field).

Entities:  

Keywords:  Adipose tissue; Immune cells; Inflammation; Insulin resistance; Obesity; Type 2 diabetes

Year:  2021        PMID: 33819954     DOI: 10.6065/apem.2040188.094

Source DB:  PubMed          Journal:  Ann Pediatr Endocrinol Metab        ISSN: 2287-1012


  8 in total

1.  Commentary on "Single point insulin sensitivity estimator for predicting type 2 diabetes mellitus in obese adolescents".

Authors:  Shin-Hye Kim
Journal:  Ann Pediatr Endocrinol Metab       Date:  2022-09-30

2.  Change of obesity prevalence and lifestyle patterns before and during COVID-19 among Korean adolescents.

Authors:  Hong Kyu Park; Jung Sub Lim
Journal:  Ann Pediatr Endocrinol Metab       Date:  2022-09-30

3.  Effects of Inflammatory Factor Expression Regulated by 12/15 Lipoxygenase on Obesity-Related Nephropathy.

Authors:  Nian Liu; Yang Liu; Dan Dong; Jinyu Yu; Hang Yuan
Journal:  Nutrients       Date:  2022-06-30       Impact factor: 6.706

4.  Single Point Insulin Sensitivity Estimator for predicting type 2 diabetes mellitus in obese adolescents.

Authors:  Jaewook Ha; Ye-Rim Oh; Eungu Kang; Hyo-Kyoung Nam; Young-Jun Rhie; Kee-Hyoung Lee
Journal:  Ann Pediatr Endocrinol Metab       Date:  2022-01-25

Review 5.  Implications of Resveratrol in Obesity and Insulin Resistance: A State-of-the-Art Review.

Authors:  Thomas M Barber; Stefan Kabisch; Harpal S Randeva; Andreas F H Pfeiffer; Martin O Weickert
Journal:  Nutrients       Date:  2022-07-13       Impact factor: 6.706

Review 6.  An Explanation for the Adiponectin Paradox.

Authors:  Hans O Kalkman
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-04

7.  Positive Associations between Body Mass Index and Hematological Parameters, Including RBCs, WBCs, and Platelet Counts, in Korean Children and Adolescents.

Authors:  Hwal Rim Jeong; Hae Sang Lee; Young Suk Shim; Jin Soon Hwang
Journal:  Children (Basel)       Date:  2022-01-14

8.  Hemoglobin and hematocrit levels are positively associated with blood pressure in children and adolescents 10 to 18 years old.

Authors:  Hwal Rim Jeong; Young Suk Shim; Hae Sang Lee; Jin Soon Hwang
Journal:  Sci Rep       Date:  2021-09-24       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.